Education
About Us
Working with TipRanks
Follow Us
Immuron Ltd (IMRN)
NASDAQ:IMRN
IMRN Stock Chart & Stats
$0.82
-$0.03(-1.20%)
At close: 4:00 PM EST
$0.82
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$0.68 - $2.39
Previous CloseN/A
Volume5.19K
Average Volume (3M)75.95K
Market Cap
$6.20M
Enterprise Value-$3.03M
Total Cash (Recent Filing)$9.99M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Aug 28, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding8,166,340
10 Day Avg. Volume112,552
30 Day Avg. Volume75,952
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.90
Price to Sales (P/S)2.09
P/FCF Ratio-2.49
Enterprise Value/Market Cap-0.49
Enterprise Value/Revenue-0.34
Enterprise Value/Gross Profit-0.53
Enterprise Value/Ebitda0.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$6.31M
Bulls Say, Bears Say
Bulls Say
Low LeverageImmuron's very low debt-to-equity (0.0145) indicates a conservative capital structure that reduces refinancing and distress risk. This balance-sheet conservatism gives management flexibility to fund commercialization and R&D initiatives over the next several quarters without heavy interest burden.
Core Product Sales MomentumSustained Travelan sales growth, with Q2 sequential gains and regional rebounds, shows market traction for its OTC gastrointestinal franchise. Combined with national ProIBS rollout, this product momentum and retail expansion create a durable revenue base to scale marketing ROI and support mid-term commercialization.
Non-dilutive R&D Cash SupportThe A$1.12m R&D tax incentive provides immediate non-dilutive cash to fund sales and development activities while preserving equity. This improves near-term liquidity and funds targeted investments to pursue FY26 EBITDX improvements, helping bridge the company through commercialization inflection points without diluting shareholders.
Bears Say
Declining Revenue & Negative MarginsA recent material revenue decline and persistently negative net/EBIT/EBITDA margins indicate the business is not yet profitable at scale. Enduring margin deficits reduce internal funding capacity, make investment cycles reliant on external capital, and pressure long-term sustainability if improvement isn't sustained.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flows, with steep FCF deterioration, signal the company burns cash to run and grow. This structural cash shortfall constrains reinvestment, increases dependence on financing, and raises execution risk for commercialization and R&D over the coming months.
Revenue Concentration RiskA large share of sales tied to a single OTC product (Travelan) creates concentration risk: adverse retail, competitive or regulatory changes in that category could materially impact revenues. Although ProIBS was launched, limited product breadth leaves the company exposed until portfolio diversification gains scale.
Immuron News
IMRN FAQ
What was Immuron Ltd’s price range in the past 12 months?
Immuron Ltd lowest stock price was $0.68 and its highest was $2.39 in the past 12 months.
What is Immuron Ltd’s market cap?
Immuron Ltd’s market cap is $6.20M.
When is Immuron Ltd’s upcoming earnings report date?
Immuron Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 158 days.
How were Immuron Ltd’s earnings last quarter?
Immuron Ltd released its earnings results on Feb 25, 2026. The company reported -$0.199 earnings per share for the quarter, missing the consensus estimate of -$0.007 by -$0.192.
Is Immuron Ltd overvalued?
According to Wall Street analysts Immuron Ltd’s price is currently Overvalued.
Does Immuron Ltd pay dividends?
Immuron Ltd does not currently pay dividends.
What is Immuron Ltd’s EPS estimate?
Immuron Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immuron Ltd have?
Immuron Ltd has 8,166,340 shares outstanding.
What happened to Immuron Ltd’s price movement after its last earnings report?
Immuron Ltd reported an EPS of -$0.199 in its last earnings report, missing expectations of -$0.007. Following the earnings report the stock price went up 17.103%.
Which hedge fund is a major shareholder of Immuron Ltd?
Currently, no hedge funds are holding shares in IMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuron Ltd
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---